John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Washam, Jeffrey B., Stefan H. Hohnloser, Renato D. Lopes, Daniel M. Wojdyla, Dragos Vinereanu, John H. Alexander, Bernard J. Gersh, et al. “Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.” J Thromb Thrombolysis 47, no. 3 (April 2019): 345–52. https://doi.org/10.1007/s11239-019-01823-y.

PMID
30790160
Full Text

Ranney, David N., Judson B. Williams, Hillary Mulder, Daniel Wojdyla, Morgan L. Cox, C Michael Gibson, Michael J. Mack, Mani A. Daneshmand, John H. Alexander, and Renato D. Lopes. “Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial).” Am J Cardiol 123, no. 4 (February 15, 2019): 571–75. https://doi.org/10.1016/j.amjcard.2018.11.029.

PMID
30538035
Full Text

Fanaroff, Alexander C., Robert Clare, Karen S. Pieper, Kenneth W. Mahaffey, Chiara Melloni, Jennifer B. Green, John H. Alexander, et al. “Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.” Circulation 139, no. 7 (February 12, 2019): 863–73. https://doi.org/10.1161/CIRCULATIONAHA.118.037202.

PMID
30586739
Full Text

Christersson, Christina, Lars Wallentin, Ulrika Andersson, John H. Alexander, Marco Alings, Raffaele De Caterina, Bernard J. Gersh, et al. “Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.” Heart 105, no. 3 (February 2019): 235–42. https://doi.org/10.1136/heartjnl-2018-313351.

PMID
30209126
Full Text

Alexander, Karen P., Marc A. Brouwer, Hillary Mulder, Dragos Vinereanu, Renato D. Lopes, Marco Proietti, Sana M. Al-Khatib, et al. “Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.” Am Heart J 208 (February 2019): 123–31. https://doi.org/10.1016/j.ahj.2018.09.017.

PMID
30579505
Full Text

Gibson, C Michael, Mathieu Kerneis, Megan K. Yee, Yazan Daaboul, Serge Korjian, Ali Poyan Mehr, Pierluigi Tricoci, et al. “The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.” Am Heart J 208 (February 2019): 81–90. https://doi.org/10.1016/j.ahj.2018.11.008.

PMID
30580130
Full Text

McGuire, Darren K., John H. Alexander, Odd Erik Johansen, Vlado Perkovic, Julio Rosenstock, Mark E. Cooper, Christoph Wanner, et al. “Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.” Circulation 139, no. 3 (January 15, 2019): 351–61. https://doi.org/10.1161/CIRCULATIONAHA.118.038352.

PMID
30586723
Full Text

Rosenstock, Julio, Vlado Perkovic, Odd Erik Johansen, Mark E. Cooper, Steven E. Kahn, Nikolaus Marx, John H. Alexander, et al. “Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.” Jama 321, no. 1 (January 1, 2019): 69–79. https://doi.org/10.1001/jama.2018.18269.

PMID
30418475
Full Text

Smith, Patrick J., Jeffrey N. Browndyke, Zachary A. Monge, Todd B. Harshbarger, Michael L. James, Jeffrey G. Gaca, John H. Alexander, et al. “Longitudinal Changes in Regional Cerebral Perfusion and Cognition After Cardiac Operation.” Ann Thorac Surg 107, no. 1 (January 2019): 112–18. https://doi.org/10.1016/j.athoracsur.2018.07.056.

PMID
30253158
Full Text

Pages